Análise e Acompanhamento da Execução de Soluções de Melhoria de Conforto Térmico na Reabilitação de Edifícios

O presente relatório inserido na Unidade Curricular de DIPRE do Mestrado em Engenharia Civil – Ramo de Construções, do Instituto Superior de Engenharia do Porto e desenvolvido no âmbito do estágio curricular realizado na empresa Porto Vivo, SRU, tem como objetivo descrever as atividades realizadas durante o período de estágio, no Núcleo de Gestão de Obras, tais como o acompanhamento das Operações de Reabilitação e Realojamento no Morro da Sé, participações em reuniões de obra com empreiteiros e projetistas, realização de vistorias para determinar o nível de conservação dos edifícios. Irá ainda ser abordado um caso de estudo relativo ao comportamento térmico da fração autónoma de um edifício em reabilitação, utilizando como base o Regulamento de Desempenho Energético dos Edifícios de Habitação (REH). Por último, as conclusões finais do estágio, a apreciação das atividades desenvolvidas, a sua importância para o estagiário a nível pessoal e profissional e ainda as ilações referentes ao caso de estudo.As part of DIPRE class of Civil Engineering’s – Construction Business - Master Course at Instituto Superior de Engenharia do Porto, the present report was developed under the internship held at Porto Vivo – SRU, it aims to describe the activities performed under the internship period, at Núcleo de Gestão de Obras the tasks of the monitoring of the rehabilitation and resettlement operations of Morro da Sé, participation of site meetings with contractors and designer managers and undertaken of surveys to determine the building’s conservation level. It will also be discussed a study case, related with the thermal behavior of an autonomous fraction from a building undertaking rehabilitation works, based on Regulamento de Desempenho Energético dos Edifícios de Habitação (REH). At last, it will be presented the internship’s final conclusions, the assessments of developed activities and its importance for the trainee at a personal and professional level as well as the conclusions from the study case

Severe Hypercalcemia Caused by Calcium-Alkali Syndrome after 15 Years of Postoperative Hypoparathyroidism in a Patient with Undiagnosed Hyperaldosteronism

Introduction. The triad of hypercalcemia, metabolic alkalosis, and acute kidney injury associated with ingesting high doses of calcium and absorbable bases characterizes the calcium-alkali syndrome. Clinical Case. We report the case of a patient with postthyroidectomy hypoparathyroidism 15 years ago due to differentiated thyroid cancer who presented with severe hypercalcemia. He had adequate control of calcemia for many years on treatment with calcitriol and calcium carbonate and hypertension treated with amlodipine, losartan, and hydrochlorothiazide. After a period of loss to follow-up, he suddenly presents with severe hypercalcemia, metabolic alkalosis, and loss of renal function. Upon hydration and withdrawal of calcitriol and calcium replacements, hypercalcemia resolved. The etiological investigation identified no granulomatous or neoplastic diseases, but an aldosterone-producing adrenal incidentaloma was found. The cause of hypercalcemia in this patient was calcium-alkali syndrome due to calcium carbonate replacement potentiated by hydrochlorothiazide and primary aldosteronism. Six months after the hospitalization and suspension of calcium and vitamin D, the patient returned to hypocalcemia, reinforcing the diagnosis. Conclusion. Although seldom described, the calcium-alkali syndrome is an expected complication for individuals with postoperative hypoparathyroidism, as they require lifelong calcium and vitamin D supplementation. This case also shows the importance of hydrochlorothiazide use and primary aldosteronism as possible triggers of life-threatening hypercalcemia

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

Abstract The use of dipeptidyl peptidase-4 (DPP-4) inhibitors may be associated with pancreatic cancer and acute pancreatitis. Recent meta-analyses have reported conflicting findings. Therefore, we performed a meta-analysis to assess the risk of both pancreatic cancer and acute pancreatitis associated with the use of DPP-4 inhibitors. We also used trial sequential analysis to evaluate whether the number of patients included was enough to reach conclusions. We included randomised controlled trials lasting 24 weeks or more that compared DPP-4 inhibitors with placebo or other antihyperglycaemic agents. A total of 59,404 patients were included. There was no relationship between the use of DPP-4 inhibitors and pancreatic cancer (Peto odds ratio 0.65; 95% CI 0.35–1.21), and the optimal sample size was reached to determine a number needed to harm (NNH) of 1000 patients. DPP-4 inhibitors were associated with increased risk for acute pancreatitis (Peto odds ratio 1.72; 95% CI 1.18–2.53), with an NNH of 1066 patients, but the optimal sample size for this outcome was not reached. In conclusion, there is no association between DPP-4 inhibitors and pancreatic cancer, and a small risk for acute pancreatitis was observed with DPP-4 inhibitor use, although the latter finding is not definitive